[18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives

被引：21

作者：

Kanoun, Salim ^{[1
]}

Rossi, Cedric ^{[2
,3
]}

Casasnovas, Olivier ^{[3
,4
]}

机构：

[1] Inst Claudius Regaud, Dept Nucl Med, F-31100 Toulouse, France

[2] Univ Toulouse, Univ Toulouse III Paul Sabatier, CNRS, CRCT,INSERM,UMR1037,ERL5294, F-31100 Toulouse, France

[3] CHU Dijon, Hematol Clin, F-21000 Dijon, France

[4] Univ Bourgogne Franche Comte, INSERM, UMR1231, F-21000 Dijon, France

来源：

CANCERS | 2018年 / 10卷 / 05期

关键词：

Hodgkin Lymphoma; F-18]FDG; PET/CT; staging; treatment response; interim PET; total metabolic tumor volume; POSITRON-EMISSION-TOMOGRAPHY; METABOLIC TUMOR VOLUME; EARLY CHEMOTHERAPY INTENSIFICATION; IMPORTANT PROGNOSTIC-FACTOR; PROGRESSION-FREE SURVIVAL; BONE-MARROW BIOPSY; INTERIM-PET; INTERPRETATION CRITERIA; COMPUTED-TOMOGRAPHY; RESPONSE ASSESSMENT;

D O I：

10.3390/cancers10050145

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Functional imaging using 18-fluorodeoxyglycose ([F-18]FDG) positron emission tomography combined with computed tomography (PET/CT) has become a major imaging modality in Hodgkin lymphoma. This imaging modality allows for a significant improvement in staging, increased sensitivity, which involves differentiating residual tumors from fibrosis during assessment, and highly impacts treatment decisions into new PET-driven strategies. This review presents the main scientific data concerning the current applications of [F-18]FDG-PET/CT in Hodgkin lymphoma at baseline, interim, and the end of treatment evaluation along with the main PET-driven trials for therapeutic decisions. The emergence of total metabolic tumor volume as a new functional prognostic factor will also be discussed.

引用

页数：11

共 44 条

[1] Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation [J].

Akhtari, Mani ;

Milgrom, Sarah A. ;

Pinnix, Chelsea C. ;

Reddy, Jay P. ;

Dong, Wenli ;

Smith, Grace L. ;

Mawlawi, Osama ;

Abou Yehia, Zeinab ;

Gunther, Jillian ;

Osborne, Eleanor M. ;

Andraos, Therese Y. ;

Wogan, Christine F. ;

Rohren, Eric ;

Garg, Naveen ;

Chuang, Hubert ;

Khoury, Joseph D. ;

Oki, Yasuhiro ;

Fanale, Michelle ;

Dabaja, Bouthaina S. .

BLOOD, 2018, 131 (01) :84-94

[2] Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial [J].

Andre, Marc P. E. ;

Girinsky, Theodore ;

Federico, Massimo ;

Reman, Oumedaly ;

Fortpied, Catherine ;

Gotti, Manuel ;

Casasnovas, Olivier ;

Brice, Pauline ;

van der Maazen, Richard ;

Re, Alessandro ;

Edeline, Veronique ;

Ferme, Christophe ;

van Imhoff, Gustaaf ;

Merli, Francesco ;

Bouabdallah, Reda ;

Sebban, Catherine ;

Specht, Lena ;

Stamatoullas, Aspasia ;

Delarue, Richard ;

Fiaccadori, Valeria ;

Bellei, Monica ;

Raveloarivahy, Tiana ;

Versari, Annibale ;

Hutchings, Martin ;

Meignan, Michel ;

Raemaekers, John .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (16) :1786-+

[3]

[Anonymous], 2015, BLOOD, DOI [DOI 10.1182/BLOOD.V126.23.577.577, 10.1182/blood.V126.23.577.577]

[4] Gonadal Function and Fertility in Survivors After Hodgkin Lymphoma Treatment Within the German Hodgkin Study Group HD13 to HD15 Trials [J].

Behringer, Karolin ;

Mueller, Horst ;

Goergen, Helen ;

Thielen, Indra ;

Eibl, Angelika Diana ;

Stumpf, Volker ;

Wessels, Carsten ;

Tz, Martin Wiehlpu ;

Rosenbrock, Johannes ;

Halbsguth, Teresa ;

Reiners, Katrin S. ;

Schober, Thomas ;

Renno, Jorg H. ;

von Wolff, Michael ;

van der Ven, Katrin ;

Kuehr, Marietta ;

Fuchs, Michael ;

Diehl, Volker ;

Engert, Andreas ;

Borchmann, Peter .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) :231-239

[5] International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers [J].

Biggi, Alberto ;

Gallamini, Andrea ;

Chauvie, Stephane ;

Hutchings, Martin ;

Kostakoglu, Lale ;

Gregianin, Michele ;

Meignan, Michel ;

Malkowski, Bogdan ;

Hofman, Michael S. ;

Barrington, Sally F. .

JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (05) :683-690

[6] Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group [J].

Borchmann, Peter ;

Haverkamp, Heinz ;

Lohri, Andreas ;

Mey, Ulrich ;

Kreissl, Stefanie ;

Greil, Richard ;

Markova, Jana ;

Feuring-Buske, Michaela ;

Meissner, Julia ;

Duehrsen, Ulrich ;

Ostermann, Helmut ;

Keller, Ulrich ;

Maschmeyer, Georg ;

Kuhnert, Georg ;

Dietlein, Markus ;

Kobe, Carsten ;

Eich, Hans ;

Baues, Christian ;

Stein, Harald ;

Fuchs, Michael ;

Diehl, Volker ;

Engert, Andreas .

LANCET ONCOLOGY, 2017, 18 (04) :454-463

[7] Current and future immunotherapeutic approaches in Hodgkin lymphoma [J].

Broeckelmann, Paul J. ;

Borchmann, Peter ;

Engert, Andreas .

LEUKEMIA & LYMPHOMA, 2016, 57 (09) :2014-2024

[8] RESIDUAL MASS IN LYMPHOMA MAY NOT BE RESIDUAL DISEASE [J].

CANELLOS, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (06) :931-933

[9]

CARBONE PP, 1971, CANCER RES, V31, P1860

[10] Cost Effectiveness of Positron Emission Tomography in Patients With Hodgkin's Lymphoma in Unconfirmed Complete Remission or Partial Remission After First-Line Therapy [J].

Cerci, Juliano J. ;

Trindade, Evelinda ;

Pracchia, Luis F. ;

Pitella, Felipe A. ;

Linardi, Camila C. G. ;

Soares, Jose, Jr. ;

Delbeke, Dominique ;

Topfer, Leigh-Ann ;

Buccheri, Valeria ;

Meneghetti, Jose C. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) :1415-1421

← 1 2 3 4 5 →